Lonza Amaxa 4D-Nucleofector system

Monday, 02 August, 2010 | Supplied by: Capsugel Australia Pty Ltd


The Amaxa Nucleofector technology is claimed to be the first efficient non-viral transfection method for primary cells and hard-to-transfect cell lines.

With a new platform, the 4D-Nucleofector system enables nucleofection of cells in several formats, combined with good performance and convenience.

Its features include: transfection of variable cell numbers with same conditions; choice of throughputs from 1 to 16 wells in just 10 s; nucleofection of adherent cells for functional assays at various cellular stages.

The modular system will accommodate upcoming transfection challenges and a current transfection protocol database is available with 690 cells listed, which is continuously updated.

Online: www.capsugel.com
Phone: 1300 657508
Related Products

Enzo Life Sciences SUPERKILLERTRAIL protein (soluble) (human), (recombinant)

Enzo Life Sciences' SUPERKILLERTRAIL (soluble) (human), (recombinant) is an enhanced ligand...

Diaclone ELISpot Kits

Diaclone's ELISpot Kits are highly specific immunoassays for the analysis of the production...

Bio-Rad Laboratories Bio-Plex Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays

The assays allow scientists to measure neutralising antibodies quickly and efficiently against...


  • All content Copyright © 2022 Westwick-Farrow Pty Ltd